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Mice  that  have  been  exposed  to  subcarcinogenic  doses  of uhraviolet  radiation 
(UV) 1 are generally incapable of rejecting a highly immunogenic UV-induced tumors 
(1-4). Thus, transplanted  fragments of these tumors, which are rejected regularly by 
normal  syngeneic  mice,  grow  progressively  in  a  large  proportion  of UV-treated 
animals.  This  lack of tumor rejection  has  been  attributed  to  the  fact  that  UV  has 
certain suppressive effects on the immune system, such as potentiating the induction 
of T  suppressor ceils (5, 6). These suppressor ceils prevent the rejection of UV-induced 
syngeneic tumors, but not allogeneic tumors or non-UV-induced syngeneic tumors (6, 
7). 
Two important  questions  about  these  UV-induced suppressor  cells  remain  unre- 
solved. One concerns the type of immune response that is decreased or prevented by 
the suppressor ceils; the second relates to the specificity of the reaction that ultimately 
is  responsible  for  tumor  rejection.  In  spite  of the  fact  that  UV-treated  mice  have 
suppressor T  cells that inhibit tumor rejection, there is some evidence that such UV- 
treated  animals  can  still  mount  certain  immune  responses  to  individually  specific 
antigens  on these  tumors  (3,  8,  9).  Thus,  it  is  possible  that  UV-induced  suppressor 
cells  prevent  the  reaction  against  common  (cross-reactive)  antigens  shared  among 
UW-induced tumors, and that these antigens are the only antigens that are important 
for tumor rejection; especially because cross-protection among UV tumors has been 
observed  (8).  An  alternative  hypothesis  is  that  the  regulatory  immune  responses  to 
UV-induced  tumors  by  suppressor  or  helper  T  cells  are  predominantly  directed 
against the common UV antigen, whereas immunologic effector reactions (e.g., T  cell- 
mediated cytotoxicity and delayed-type hypersensitivity)  are predominantly directed 
against individually specific tumor antigens. This latter possibility is more in keeping 
with our previous studies  (10-12) showing that selective elimination of tumor-specific 
immunity by anti-idiotype suppression  or loss of the tumor-specific antigen  is associ- 
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ated with the progressive growth of these tumors in unirradiated mice. 
In the studies reported here, we have begun to address these issues by examining 
the  antitumor  immune  responses  that  are  generated  in  UV-treated  mice  under 
conditions that  do  or do  not lead  to  progressive tumor growth  of the  UV-induced 
tumor  1591-RE.  Two  different  approaches  were  used:  in  the  first,  the  immune 
responses  to  the  tumors  were  determined  using tumor  resistance  and  cytolytic T 
lymphocyte reactivity as measures of immunity; in the second, an analysis of antigen- 
icity and growth behavior was performed on tumors that were recovered after growth 
in UV-treated mice, to determine whether immunoselection had occurred. We show 
here  that  tumors  reisolated  after  transplantation of the  1591-RE  tumor into UV- 
suppressed  mice  have  regularly lost  a  tumor-specific determinant that  is  uniquely 
expressed  on the  original  1591-RE  tumor.  This was  in striking contrast  to  tumors 
reisolated after injection of 1591-RE into nude or anti-idiotypically suppressed mice. 
Furthermore, a  large percentage of the  tumors reisolated after transplantation into 
UV-suppressed mice had changed to progressor tumors that were no longer rejected 
by normal mice. Our results emphasize the importance of tumor-specific immunity 
and suggest that partial immune suppression such as that caused by UV may favor 
the  frequent appearance of immunoselected progressor tumor variants from highly 
immunogenic regressor tumors such as  1591-RE. 
Materials and Methods 
Mice.  5-10-wk-old female C3H/HeN (mammary tumor virus-negative) mice from a colony 
of germ-free-derived, specific pathogen-free animals were purchased from the Frederick Cancer 
Research Facility. They were kept at the La Rabida Institute in laminar flow hoods and were 
given sterilized food  (Teklad L-485  for autoclaving, Harlan Sprague Dawley Inc., Madison, 
WI) and water. UV treatment of mice was done at the Frederick Cancer Research Facility as 
described earlier (6). Briefly, beginning  at 8 wk of age, mice were shaved weekly on the dorsum 
and housed 20 cm below a bank of six Westinghouse FS40 sun lamps. They were irradiated for 
1 h  three times per wk  for  3 mo before their use at  an irradiance of ~2 J/m2/s.  This UV 
treatment has been shown repeatedly to induce susceptibility to challenge with UV-induced 
tumors that lasts for at least 6 mo in the absence of further treatments (2). None of the animals 
had developed primary tumors from the UV at the time of these experiments. Age- and sex- 
matched untreated mice served as controls for  the UV-treated group. The original stock  of 
nude C3H mice was in the 23rd backcross  generation when it was obtained from a colony at 
the Biology Division of the Oak Ridge National Laboratory. 
Fibrosarcoma Lines.  The fibrosarcomas  1591-RE,  1316-RE,  and 2240-RE were induced in 
C3H/HeN  (mammary tumor virus-negative) mice by repeated  exposure  to  UV  (2). These 
fibrosarcomas have non-cross-reacting tumor-specific transplantation antigens, and they are 
strongly immunogenic in that they regress when transplanted into young syngeneic mice, after 
an initial period of growth during the first  1-2 wk (6). Variant tumors 1591-PRO.1 to  1591- 
PRO.4 were derived from each of four progressively  growing tumors observed in 5 out of 100 
unirradiated animals implanted with  fragments  of the  fifth  transplant  generation of  the 
parental 1591 regressor tumor (referred  to here as 1591-RE), as described previously (12). These 
progressor variant tumors no longer express the 1591-RE tumor-specific antigen (12). As control 
tumors, we also used four 1591 tumors, I591-IS24T1 to 1591-IS24T2,  that were reisolated from 
anti-idiotypically  suppressed mice developing progressive  tumor growth after injection of 1591- 
RE tumor cells  (experiment 2 in ref.  10). All of the fibrosarcomas used in this study grow 
progressively  in nude mice, syngeneic UV-treated mice, or thymectomized and x-irradiated 
mice, and eventually kill these hosts (2). Using previously described methods (12), tumors were 
adapted to growth in vitro, and expanded in tissue  culture within 2 wk of explanation, and 
cryopreserved in aliquots (13) unless otherwise indicated. Whenever tumor cells were required 
for  experiments,  selected  frozen  aliquots  were  thawed  and  used  within  24  h.  For  tumor URBAN, HOLLAND, KRIPKE,  AND SCHREIBER  1027 
challenge, solid tumors grown in vivo were implanted as viable 1-mm  3 fragments subcutaneously 
with a trocar into both inguinal regions, or cell suspensions from cultured cells were injected 
intraperitoneally  or subcutaneously underneath the ventral skin. 
Generation of Cytotoxic Lymphocytes In Vitro  and In Vitro.  Tumor-specific  cytotoxic T lymphocytes 
were  generated from spleen cells of animals immunized with either two  1-mm  3 fragments of 
solid tumor implanted subcutaneously with a trocar, or a single subcutaneous injection of 107 
viable tumor cells. Spleen cells from tumor-immune animals were restimulated in vitro in a 
mixed lymphocyte-tumor cell  culture  (MLTC)  as  previously described  (12). The syngeneic 
continuous T  cell  lines were a  gift  of Richard D.  Wortzel, University of Chicago, and were 
derived from syngeneie MLTC cells specific for determinants uniquely  expressed by tumor cells 
of the 1591 tumor lineage (14); a detailed characterization of these T cell lines will be published 
separately (R. D. Wortzel, manuscript in preparation). Cytolytic peritoneal lymphocytes were 
induced by a modification of the method described previously by Newcomb et al. (15). Mice 
were  injected  once  intraperitoneally with  1  ×  10  v cultured  tumor  cells,  and  8  d  later, 
nonadherent peritoneal cells were recovered and used as effectors for a 6-h SlCr-release assay as 
described previously (12). 
Limiting  Dilution Analysis.  MLTC  were  set  up  as  microcultures in 6  ×  50-mm  round- 
bottomed glass tubes (Kimble Div., Owens-Illinois, Inc., Toledo, OH). Each well contained, in 
a  volume of 0.4  ml MLTC medium (containing 33% secondary mixed lymphocyte culture 
supernatant) (16), serially diluted numbers of responder spleen cells,  106 x-irradiated (2,000 
rad) spleen cells as fillers, and 2 ×  103 mitomycin C-treated 1591-RE tumors cells. After 7 d of 
incubation in an upright position, the cells of each microculture were resuspended by vigorous 
pipetting, and  the  suspension was  split  into  two  150  /L1  aliquots that  were  transferred  to 
corresponding wells of two different microtitration plates for analysis in a 51Cr-release assay. 
The frequency ofcytotoxic lymphocyte precursors (CLP) was determined using Poisson limiting 
dilution formalism as  described by Lefkovits  and Waldmann (17). A  culture was  scored  as 
positive if its 51Cr-release value was more than three standard deviations above the mean of the 
spontaneous release value. 
Cr-Release Assay.  Cytotoxicity was determined by the ability of effectors to lyse 5XCr-labeled 
target cells during a 6-h assay as described (12). The percentage of specific lysis was calculated 
by the formula:  ([experimental release  -  spontaneous release]/[total release  -  spontaneous 
release])  ×  100. 
In some  experiments, effector  cells  were  depleted  of Lyt-2  + cells  by  incubation with  a 
monoclonal antibody of the anti-Lyt-2 IgM hybridoma 2.155.2  (18), a gift of Dr. F. W. Fitch 
of the University of Chicago, and rabbit complement as described (12). 
Results 
Comparison  of 1591-RE  Tumor Resistance  of Normal,  UV-treated,  and Nude  Mice.  We 
first compared the ability of normal, UV-treated, and nude mice to resist a  primary 
subcutaneous challenge with  varying numbers of  1591-RE  tumor cells.  Single-cell 
suspensions were obtained from an established tissue culture cell line of 1591-RE, and 
1-mm  3 fragments were prepared from a solid 1591-RE tumor taken from a nude C3H 
mouse that had been injected with the same tissue culture cell line. In agreement with 
earlier reports  (3, 4), Table I  shows that UV-treated animals, in contrast to normal 
mice, were highly susceptible to challenges with fragments or larger doses (5 ×  107) of 
cultured 1591-RE tumor cells. In fact, the  1591-RE fragments failed to grow in only 
5  of 23  UV-treated  mice.  (Further  analysis of the  immune response of these  five 
"exceptional"  mice  will  be  presented  below  in  Table  II.)  However,  UV-treated 
animals, like normal mice, resisted challenges of lower doses  (2 ×  106 or  1 ×  107) of 
tumor  cells.  This  relative  resistance  probably was  not  caused  by  insufficient UV 
treatment, as  3  of 10  uninjected animals from  the same batch of UV-treated mice 
subsequently developed  autochthonous  tumors  on  their  dorsal  skin  >6  mo  later, 
showing that these mice had received a  carcinogenic dose of UV. The lower doses of 1028  TUMOR VARIANT SELECTION  BY  IMMUNOSUPPRESSED  HOSTS 
TABLE  I 
Growth of Various Numbers of Transplanted 1591-RE Tumor Cells in Normal, 
UV-treated, and Nude Mice 
Inoculum of 1591-RE* 
Tumor incidence:~ 
Normal  UV-treated  Nude 
2 ×  106 tumor cells  0/10 (0)  0/9  (0)  4/4  (100) 
I  ×  107 tumor cells  0/47 (0)  0/7  (0)  7/7  (100) 
5  ×  107 tumor cells  0/3  (0)  3/3  (100)  1/1  (100) 
Two 1-mm  a fragments  0/37 (0)  18/23 (78)  10/10 (100) 
* C3H mice were injected with 1591-RE tumor cells or viable tumor fragments, and the tumor 
incidence was determined 6 wk later. For challenges consisting of 2 ×  106 or I ×  107 tumor cells, 
about one-half of the mice were injected intraperitoneally and the other half subcutaneously. All 
challenges consisting of 5 x  107 tumor cells or two I-mm  a fragments were administered subcuta- 
neously, and all challenges  were given on the ventral aspect of the mice 7 d after lhe last exposure 
to UV. All animals that had tumors at 6 wk eventually died because of progressive tumor growth. 
The data are pooled from three independent experiments. 
:~ Number of mice with progressively growing tumors/number challenged. Parentheses indicate 
percentage of mice affected. 
tumor cells that failed to grow in UV-treated mice were highly tumorigenic in nude 
mice; this suggested that a T  cell-dependent mechanism might be responsible for the 
tumor regression observed  in UV-treated  mice at  the  low  cell  inoculum. We  next 
determined whether the UV-treated animals that  rejected  a  small primary dose of 
1591-RE  tumor cells were  resistant  to  a  secondary challenge with  1591-RE  tumor 
fragments.  Thus, eight  UV-treated  animals were  injected with  107  1591-RE  tumor 
cells,  and  1  mo  later  received  implants consisting of two  l-ram  3  1591-RE  tumor 
fragments.  Table II  shows  that  all of these  UV-treated animals were  now as  fully 
capable of rejecting the  1591-RE fragment challenge as all of 27  normal unprimed 
animals tested.  In  contrast,  all  of  12  UV-treated  control  mice  and  9  of  10  nude 
animals that had not been preimmunized were fully susceptible to progressive tumor 
growth,  As  might  be  expected,  all  of the  5  exceptional  UV-treated  animals that 
rejected a  primary challenge of 1591-RE tumor fragments without preimmunization 
(5 out of 23 animals in Table I) were also resistant to a secondary challenge with these 
fragments. Table II also shows the specificity of the immune response in vitro of the 
UV-treated mice that had resisted a secondary challenge with fragments of the  1591- 
RE tumor. For this analysis, the spleen cells of these animals were restimulated with 
1591-RE tumor cells in vitro in an MLTC  3  wk after the last tumor challenge. The 
cultures were  then  tested  for  specific cytolytic activity in a  short-term SlCr-release 
assay. We found that those UV-treated animals that had been immunoprotected by 
preimmunization generated  1591-RE-specific cytolytic T  cells in culture, similarly to 
normal  immune mice.  Thus,  their  restimulated spleen  cells  lysed  1591-RE  tumor 
targets but not 2240-RE or  1316-RE control tumor targets. 
Generation of Tumor-specific Immune Responses by UV-treated Mice.  To further delineate 
the  conditions under which  UV-irradiated  mice  would  respond  specifically to  the 
1591-RE  tumor,  we  used  an  in  vivo  system  for  the  generation  of  cytotoxic  T 
lymphocytes.  Normal,  UV-treated,  and  nude  mice  were  challenged with  a  single 
intraperitoneal injection of 1 ×  10 7  1591-RE tumor cells, or with two such injections 
3 wk apart. These injections did not result in tumor growth in UV-treated or normal 
mice,  but  did  result  in progressive  tumor growth  in  nude mice.  8  d  after  the  last URBAN, HOLLAND, KRIPKE,  AND SCHREIBER  1029 
TABLE II 
Tumor Resistance and Specificity of Cytolytic Responses of UV-treated Animals Rejecting a Previous 
Challenge of the 1591-RE Tumor 
Mice 
Outcome of suhse-  Number 
Type of preimmuniza-  quent challenge  of mice 
tion with 1591-RE  with 1591-RE  tested in 
tumor cells  fragments  (tumor  MLTC 
incidence) 
Percent lysis  of target cells* 
1591-RE  2240-RE  1316-RE 
Normal  None  Rejected (0/27)  10  83 +-- 2:1:  5 + 2  4 +  1 
1 ×  10  7 tumor  cells  Rejected  (0/5)  5  85 4- 2  3 4- 2  1 --+- 2 
Two l-ram  3 fragments  Rejected  (0/6)  6  82 + 6  12 + 8  l 1 4- 4 
UV-treated  None  Accepted (12/12)  8  29 +__ 4  24 ----- 5  29 + 5 
1 ×  107 tumor cells  Rejected  (0/8)  8  83 + 2  -1 ±  1  1  ±  4 
Two l-mm  3 fragments  Rejected  (0/5)§  5  64 + 4  8 ± 4  7 4- 4 
Nude  None  Accepted (9/10)  .... 
* C3H mice were challenged once or twice, as indicated, with 1591-RE tumor cells subcutaneously. 3 wk 
after the last tumor challenge, the spleen cells of the animals were restimulated for 6 d with 1591-RE 
stimulator cells and then tested in a 5~Cr-release assay against the indicated target cells (E/T ratio 5:1). 
:l: Mean + SEM for the number of animals indicated, individually analyzed in four separate experiments. 
§ 5 of the 23 UV-treated mice that rejected the challenge with fragments in experiments shown in Table 
I. 
immunization, the peritoneal exudate cells of these animals were removed, depleted 
of adherent cells, and tested for cytolytic activity in a  ~lCr-release assay. The results 
from three independent experiments were similar, and therefore were pooled for Fig. 
1.  It can be seen that both normal and UV-treated mice were capable of mounting 
1591-RE-specific primary and secondary immune responses in vivo, as effector cells 
from  these  animals lysed  1591-RE  tumor cells but  not  the  unrelated UV-induced 
tumor 1316-RE. These specific effector cells were cytolytic Lyt-2  + T  cells, as treatment 
of the  peritoneal cells before  the  51Cr-release assay with  anti-Lyt-2 antiserum and 
complement abrogated  their activity.  No  cross-reactive cytotoxicity by Lyt-2  + cells 
was  observed in any of the  experiments. Not  shown  in Fig.  1 is  that  nonadherent 
peritoneal cells from five normal unimmunized control animals caused <10% specific 
lysis of  1591-RE  cells even at  a  100:1  effector/target  cell  (E/T)  ratio.  Nude  mice 
failed to generate any appreciable Lyt-2  + effector cells against the  1591-RE tumor, 
but did generate high levels of Lyt-2- effector cells against control  1316-RE tumor 
cells.  We have shown previously that  such  Lyt-2- cytolytic activity can be due  to 
natural killer cells (12). 
We  next  analyzed the  generation of cytotoxic T  lymphocytes in culture after  a 
single tumor challenge in vivo, including UV-treated mice with progressively growing 
tumor  fragments in the  analysis. Thus,  normal, UV-treated,  and  nude mice were 
challenged subcutaneously with  107  1591-RE tumor cells, or alternatively with  1591- 
RE tumor fragments. 3 wk later spleen cells were removed, restimulated for 6 d  with 
1591-RE tumor cells in an MLTC, and then tested for specific cytolytic activity in a 
51Cr-release assay. In agreement with the data obtained in the above experiments in 
vivo, the  upper panel of Fig.  2  shows  that  1591-RE-specific cytolytic T  cells were 
generated in vitro from spleens of normal and UV-treated animals injected with  107 
cultured 1591-RE cells; this dose is nontumorigenic for UV-treated or normal mice. 
These effector cells lysed neither 1316-RE nor 2240-RE control tumor cells. Further- 
more,  they  did  not  lyse progressor  variants of  1591-RE  derived  in vivo, which we 1030  TUMOR  VARIANT  SELECTION  BY  IMMUNOSUPPRESSED HOSTS 
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Fic.  1.  Induction of primary and secondary tumor-specific  immune responses in  vivo in normal 
and  UV-treated but  not  in  nude mice.  Animals received  either one  (primary response)  or  two 
(secondary response) intraperitoneal injections of 1 X  107  [591-RE  tumor cells, 3 wk apart, and 8 
d after the last  injection  their nonadherent peritoneal exudate cells were treated with anti-Lyt-2 
antiserum and/or complement before testing in a 6-h SlCr-release assay against  1591-RE or 1316- 
RE tumor target cells. Vertical bars represent the SEM of the individual analysis of three to five 
animals in three independent experiments. 
have previously shown to have lost the 1591-RE-specific determinant  (12). In contrast 
to the immune  response induced by tumor challenge of 107  1591-RE cells, challenge 
with  1591-RE  tumor  fragments produced profound differences between normal  and 
UV-treated  mice,  shown  in  the  lower  panel  of Fig.  2.  Whereas  normal  mice  that g 
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FIG.  2.  Cell-mediated immune reactivity generated in vitro by normal and UV-treated but not by 
nude mice subsequent to in vivo challenge with  l0 7  1591-RE tumor cells  (upper panels), or with 
1591-RE  tumor fragments (lower panels). Spleen cells were removed 3 wk after tumor challenge, 
restimulated in culture with the parental 1591-RE tissue culture cell line in a 6-d mixed lymphocyte- 
tumor cell  culture,  and  then  used  as  effectors  in a  6-h S]Cr-release  assay.  UV-treated animals 
generated normal tumor-specific immunity in response to an injection of 10  v 1591-RE  tumor cells, 
but generated a lower level of cross-reactive immunity in response to a challenge with fragments of 
the  tumor.  Normal  animals responded  specifically after both types  of challenge.  Vertical  bars 
represent the SEM of the individual analysis of 6-12 animals in six independent experiments. 
rejected the tumor  fragments generated  high levels of 1591-RE-specific immunity,  the 
UV-treated  mice, which showed progressive growth of the tumor  fragments, generated 
much  lower levels of cytotoxicity  that  also  appeared  to be cross-reactive.  This cross- 
reactive response was absent in spleen cell cultures of nude  mice, which  had  progres- 
sively growing tumor  fragments. 1032  TUMOR  VARIANT  SELECTION  BY  IMMUNOSUPPRESSED  HOSTS 
Analysis of the Cross-Reactive Cytolytic Immunity by Limiting Dilution.  The cross-reactive 
cytolytic activity generated  in  the spleens  of UV-treated  tumor-bearing  mice could 
represent  a  response to an antigen  shared on the different  tumor targets,  or it could 
represent  the  result  of a  polyclonal  activation  of multiple  T  lymphocyte  clones, 
including those with specificity for  1591-RE.  Limiting dilution  analysis was used to 
distinguish between these two possibilities.  Normal animals were challenged with two 
l-ram 3 fragments of the  1591-RE tumor, and UV-treated mice were challenged with 
107  1591  tumor cells or with  1591-RE tumor fragments.  3 wk after tumor challenge, 
spleen  cells  from these animals  were serially  diluted  and  restimulated  in  vitro with 
1591-RE tumor cells  as described  in  Materials  and  Methods.  At the end  of the  6-d 
culture period, each microculture was split into two separate wells and each well was 
then tested for cytolytic activity against either  1591-RE or 2240-RE tumor target cells 
in a  51Cr-release assay. The minimal  frequencies of CLP reactive with  1591-RE was 
determined  for the  three  different  groups of mice in  two  independent  experiments. 
Semilogarithmic  plots of the frequency of negative wells as a  function of the dose of 
responding cells were linear,  as seen  in Fig.  3. From the slope of the regression  lines, 
a  minimal  estimate  can be made of the  frequency of CLP  (17).  In this  manner,  the 
minimal CLP frequency for normal animals injected with  1591-RE tumor fragments 
was found to be 1 CLP/4.02 ×  104 spleen cells. The estimated minimal CLP frequency 
for UV-treated animals injected with 107 1591-RE tumor cells was practically identical 
to this and was calculated  to be  1 CLP/4.04  ×  104 spleen cells. In contrast,  the CLP 
frequency for UV-treated animals with progressively growing fragments of the  1591- 
RE tumor was only  1 CLP/1.74 ×  105 spleen cells, approximately fourfold less than 
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F~o.  3.  Decreased frequency  of CLP  in  UV-treated  animals  challenged  with  fragments  of the 
1591-RE  tumor  (0)  as compared  with  UV-treated  animals  challenged with  l07  1591-RE  tumor 
cells (C)) or with  norma! animals challenged with  ]591-RE tumor fragments (,J,). Spleen cells were 
removed 3 wk after tumor  challenge, cultured  in  limiting  numbers with  2  X  10  ~ 1591-RE  tumor 
cells  and  |0  °  irradiated  (2,000  rad)  normal  syngeneic spleen  cells  for  6  d,  and  then  tested  for 
cytolytie  activity  in  a  6-h ~ICr-release assay. All  wells with  ~IOr release values <3  SD above the 
mean of the spontaneous release level were considered negative. CLP frequencies were determined 
from  the  slopes of the  fitted  regression  lines.  Vertical  bars  indicate  the  SEM  for  two  separate 
experiments, each testing 32  160 wells/responder cell dose. URBAN,  HOLLAND, KRIPKE, AND SCHREIBER  1033 
for the other two groups of animals. 
We then  determined the specificity of individual cytotoxic cells by analyzing the 
reactivity of single split microcultures against  1591-RE  and  2240-RE  targets. It was 
apparent that  most of the individual cultures of cells from  immunized normal mice 
or from UV-treated mice injected with  107  1591-RE cells developed cytotoxic activity 
with  preferential  specificity for  1591-RE  targets,  as  most  cultures  reacted  against 
1591-RE,  but  not  against 2240-RE  (Fig. 4,  panels A  and B).  In contrast,  the cross- 
reactive cytolytic activity generated  in  cultures  of cells from  the  UV-treated  mice 
challenged with tumor fragments  (panel C)  segregated into an approximately equal 
number of CLP reactive with either  1591-RE  or the 2240-RE  target. The pattern of 
segregation  that  would  be  expected  if the  CLP  were  directed  against  an  antigen 
expressed on both  1591-RE  and 2240-RE  (common antigen) is shown in panel D, in 
which the microcultures were split and each half was tested against the same  1591- 
RE target cells. This control experiment shows that the pattern of reactivity was not 
artifactually generated  during  the  splitting of the  microcultures.  The  results  from 
panel  C  are  analyzed  further  in  Table  III,  which  indicates  that  the  degree  of 
independent  assortment  between  wells  reacting  to  1591-RE  and  wells  reacting  to 
2240-RE  target  cells  is  >75%.  This  indicated  that  the  apparent  cross-reactivity 
observed  with  spleen  cells  from  UV-treated  tumor-bearing  mice  results  from  the 
activation of multiple specific clones, and not from activation of a single clone directed 
against a  common antigen. 
Recovery of 1591-RE  Tumors  from  UV-treated Mice.  Because  UV-treated  mice were 
capable of generating tumor-specific T  cells in response to a  1591-RE tumor challenge, 
we wondered whether  the immunity  in  these mice might  select for  1591-RE  tumor 
variants during the progressive growth of the tumor. To test this possibility, 11  UV- 
treated  animals  were  challenged  with  two  1-mm  3 fragments  of the  solid  1591-RE 
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FIG. 4.  Cellular basis of the immune  response generated  by normal animals challenged  with 
fragments of the 1591-RE tumor (A), UV-treated animals challenged with 107 [  59 l-RE tumor ceils 
(B), or UV-treated animals challenged with fragments of the  1591-RE tumor (C, D). Individual 
symbols represent the analysis of single cultures, split and tested in a 51Cr-release  assay on different 
(1591-RE and 2240-RE) or the same  (1591-RE and  1591-RE) tumor target cells, as indicated. 
Cultures contained  an average of 0.5 CLP (calculated from the slopes of the corresponding fitted 
regression lines of Fig. 3). The dashed horizontal and vertical lines are 3 SD above and to the right 
of the mean of the spontaneous release values for the respective targets, our definition of positive 
cytotoxic activity. The data are pooled from two experiments,  160 cultures  analyzed in the first 
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TABLE  III 
Independent Assortment in Limiting  Dilution Analysis of Tumor-reactive CPL from  UV-treated Mice 
Bearing the 1591-RE Tumor 
Fraction of responding cultures 
Number of double 
responding cultures 
Expected 
Mean  Percent in- 
Assure-  dependent 
Experi-  CLP/  Assum-  ing in-  Ob-  assortmentll 
ment*  well:~  1591-RE  1591-RE  2240-RE  ing  depend-  served 
linked  ent as- 
assort-  sort- 
ment  ment§ 
1.0  64/96  63/96  --  63  42  62  5 
58/96  --  61/96  58  37  39  90 
0.5  34/96  33/96  --  33  12  32  5 
33/96  --  28/96  28  10  7  >100 
1.0  129/160  127/160  --  127  102  127  0 
123/160  --  97/160  97  75  79  82 
0.5  56/160  57/160  --  56  20  54  6 
31/160  --  51/160  31  10  15  76 
*  UV-treated animals were injected with two  1-mm  3 fragments of the  1591-RE tumor. 3 wk later, their 
spleen cells were cultured in microwells under limiting dilution conditions, as described in Materials and 
Methods. Microwells were split  after 6 d of incubation, and each half was tested in a 6-h 51Cr-release 
assay  on  either  different  (1591-RE  and  2240-RE)  or  the same  (1591-RE  and  1591-RE) targets,  as 
indicated. Dot plots of these responses appear in Fig. 4. 
:~ Calculated from the linear regression plot  in Fig. 3 for UV-treated mice injected with  1591-RE tumor 
fragments.  1.0 CLP/well was contained in  1.82 ×  105 responding cells. 
§ Calculated as the frequency of responders  to one target times the frequency of responders to the other 
target multiplied by the total number of cultures per target, 
]1 The  percentage of independent assortment was  calculated  by  the  formula:  100  X  (1  -  [(c  -  b)/ 
(a  -  b)]);  where a  is the expected number of double responders assuming linked assortment, b  is the 
expected number of double responders assmning independent assortment, and c is the observed number 
of double responders. 
tumor, and  1 mo later these tumors were excised and coded as  1591-UVS. 1 to  1591- 
UVS. 11.  Tissue culture cell  lines were immediately and  readily established for each 
of these  tumors  and  expanded  into  large  batches  in  <2  wk  for  cryopreservation. 
Furthermore, fragments dissected from each of these tumors were reimplanted  into 
groups of normal mice. This procedure allowed us to test for a  possible change in the 
growth  behavior of the  tumor  that  may  have  resulted  from  the  transplantation  of 
1591-RE tumor fragments into UV-treated  mice. Table IV shows that 8  out of the  11 
tumors  recovered  from  the  UV-treated  mice  had  indeed  acquired  an  increased 
tumorigenic potential in normal mice. Fragments of seven of these tumors produced 
progressively growing tumors in  50%  or more of the recipients, whereas none of the 
eight  1591-NU  tumors  reisolated after growth of 1591-RE  fragments in  nude  C3H 
mice exhibited this behavior. 
We have previously demonstrated  that progressively growing tumor  variants arise 
occasionally in  normal  mice injected with  the  1591-RE  tumor  (1591-PRO  tumors), 
and  that  these progressor variants always have lost  a  1591-RE-specific determinant 
(12).  We therefore tested whether this determinant  also had been lost from the  1591- URBAN, HOLLAND, KRIPKE,  AND SCHREIBER 
TABLE IV 
Effect of Prior Passage Through Nude or UV-treated Mice on the Growth Potential of the 
Reisolated  1591 Tumors in Normal Mice 
1035 
Experiment 
Injected 1591 tumor*  Tumor incidence:~ 
Donor  Designation  Normal mice  Nude mice 
Total 
1 
Totals 
Nude mice 
UV-treated mice 
1591-NU.1  0/18  2/2 
1591-NU.2  2/17  2/2 
1591-NU.3  0/10  4/4 
1591-NU.4  0/20  ND§ 
1591-NU.5  0/4  3/4 
159l-NU.6  0/4  1/1 
1591-NU.7  0/6  4/4 
1591-NU.8  0/8  4/4 
2/87 (2)  20/21 (95) 
1591 -UVS. 1  0/6  1/1 
1591-UVS.2  0/6  1/1 
1591  -UVS.3  4/6  1  / 1 
1591-UVS.4  5/10  2/2 
1591-UVS.5  10/38  2/2 
1591-UVS.6  4/4  4/4 
1591-UVS.7  4/4  1/1 
1591-UVS.8  0/4  1/1 
1591-UVS.9  4/4  1/1 
1591-UVS. 10  2/4  4/4 
1591-UVS. 11  4/4  3/4 
37/90  (41)  21/22 (95) 
* Normal C3H mice were challenged with two l-mm  a tumor fragments reisolated from 1591- 
RE-injected UV-treated or nude mice. 
:~ Number of mice with progressively growing tumors 6 wk after tumor challenge/number 
challenged (percent). All animals that had tumors at 6 wk eventually died because of the 
progressive tumor growth. 
§ Not done. 
UVS tumors. Thus, effector T  cells with this specificity were generated in vitro from 
the spleen cells of normal  1591-RE-immune mice in an MLTC; these effector cells 
were then used to test  1591-UVS target cells in a 51Cr-release assay. In addition, these 
targets were tested using effector cells from an established T  cell line (anti-A-I-4) that 
specifically recognizes a  1591-RE tumor-specific determinant (14).  Fig. 5  shows that 
all of the nine 1591-UVS tumors tested were highly resistant to the cytolytic effects of 
both types of 1591-specific T  lymphocytes, indicating that they no longer expressed 
this 1591-RE-specific determinant. In contrast, the tumor lines reisolated from tumors 
that  developed  in  1591-RE-injected nude mice or  tumor cell  lines reisolated  from 
tumors that developed in anti-idiotypically  suppressed mice fully retained the expres- 
sion of this tumor-specific determinant. This resistance of 1591-UVS tumors to  the 
1591-specific T  cells remained heritably stable over 3  mo of continuous passage  in 
vitro or repeated passage of the tumors in nude C3H mice (data not shown). To prove 
that the tumors reisolated from the UV-treated mice at the site of fragment implan- 
tation were actually derived from the challenge with  1591-RE tumor cells, we used a 7
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syngeneic cytolytic T  cell line (anti-B-Brl) directed against a different and independ- 
ent  1591 tumor-specific epitope that we have recently found to be retained by 1591- 
PRO tumor variants isolated from normal mice (14). We found that all nine of the 
1591-UVS tumors also retained this 1591-RE tumor-specific marker, as they remained 
as susceptible as the parental  1591-RE tumor cells to this cytolytic T  cell probe (70% 
specific lysis +3 SEM,  E/T  =  5:1), whereas control UV-induced  fibrosarcoma lines 
such as 2240-RE and  1316-RE were not lysed significantly by the same probe under 
the same conditions  (4% specific lysis +2 SEM, E/T =  5:1). 
Discussion 
One of the most intriguing features of UV-induced tumors is their often extremely 
high  immunogenicity  (1,  2).  Thus,  most  of these  tumors  are  rejected  by  normal 
syngeneic mice but they can be transplanted into nude or x-irradiated thymectomized 
mice. The fact that UV-treated mice also readily accept transplants of UV-induced 
regressor tumors (3, 4)  appears to provide a  rational explanation for the question of 
why  such  highly  immunogeneic  tumors  could  ever  arise  in  the  UV-treated  host. 
Because of this, it has been assumed that UV-treated mice do not alter the antigenic 
make-up of transplanted  UV-induced  tumors. In fact, serial passage of UV-induced 
tumors  through  UV-treated  animals  has  been  used  by some  investigators  for  the 
routine maintenance of the tumor cell lines in vivo. We show in this study that this 
assumption is unwarranted, at least for the highly immunogenic tumor 1591-RE. 
Our  data  clearly show  that  there  is a  striking  difference in  the  1591-RE  tumor 
susceptibility of nude mice and UV-treated mice. After injection of 2 ×  106 or 1 ×  107 
1591-RE tumor cells, all C3H nude mice developed tumors, whereas all of the UV- 
treated mice rejected the challenge (Table I). Only at higher doses of the tumor cells 
did nude and UV-treated animals show a  similarly high tumor incidence:  ~80% of 
UV-treated  mice  injected  with  5  ×  107  1591-RE  tumor  cells  or  1591-RE  tumor 
fragments died of progressive tumors, as did all of the nude mice injected with these 
doses of tumor cells. The exceptional 20% of UV-treated mice that rejected a challenge 
with higher doses of tumor cells were also resistant  to a  rechallenge with the tumor 
fragments, and spleen cells of these mice generated tumor-specific cytolytic immunity 
in culture (Table II). 
Previous work has already demonstrated that UV-treated mice can mount certain 
tumor-specific immune responses (3, 8, 9). The present study shows that UV-treated 
mice challenged with lower doses of 1591-RE tumor cells were as capable as normal 
mice of mounting tumor-specific primary and secondary cytolytic immune responses 
in vivo (Fig.  1) and also of generating such tumor-specific T  cells after restimulation 
in vitro (Fig. 2). Similarly, there was no difference in the minimal estimated cytolytic 
precursor frequency between these UV-treated and normal mice (Fig. 3). In contrast. 
UV-treated mice bearing progressively growing tumor fragments showed cross-reac- 
tive cytolytic immune responses in culture (Table II and Fig. 2). Analysis of this cross- 
reactive reactivity at the clonal level (Fig. 4) clearly indicated that the cross-reactivity 
was not the result of activation of clones directed against a common UV antigen, as 
the experimentally observed degree of independent reactivity of individual wells fully 
coincided  with  the  degree  of independent  reactivity  that  is  expected  statistically 
assuming  unique  reactivities  of all  clones  (Table  III). Thus,  it  appears  that  UV- 
treated mice with progressively growing tumor fragments show polyclonal activation 1038  TUMOR  VARIANT SELECTION BY IMMUNOSUPPRESSED HOSTS 
of their spleen  cells  in  culture.  Furthermore,  although  1591-RE-specific T  cells are 
then  apparently  responsible  for  the  anti-1591-RE  reactivity  in  the  cross-reactive 
response of UV-treated progressor mice, the level of reactivity is markedly reduced as 
compared with  the  level of 1591-RE  reactivity generated  by UV-treated  mice not 
bearing progressor fragments (Fig.  2).  This defect is further evidenced by the much 
lower 1591-RE-specific cytolytic precursor frequency in the spleens of these mice (Fig. 
3). 
It is clear from our data (Fig. 5) that UV-treated animals regularly selected against 
the outgrowth of 1591-RE tumor cells that express a  1591-RE tumor-specific antigen. 
In contrast to all of the UV-treated recipients,  there was no selection by any of the 
nude C3H recipients against tumor cells expressing the 1591-RE-specific determinant. 
As would be expected, normal mice whose  1591-RE-specific lymphocytes have been 
suppressed by anti-idiotypic immunity (10)  also did not select against the expression 
of this antigen. These findings taken together suggest that the selection against a  1591- 
RE tumor-specific antigen in the UV-treated host is due to immune selective pressure. 
On the other hand, we have no evidence for a selection against a common UV antigen 
during  the  development of the  1591-UVS  tumors.  In  fact,  cross-protection  among 
UV-induced tumors serially passed through UV-treated mice (19)  and the specificity 
of UV suppressor cells for UV tumors (7) may suggest the retention of such common 
UV antigens. Thus, we would like to hypothesize that the common UV antigens may 
be analogous to class II cell surface antigens coded for by the major histocompatibility 
complex (20), which are preferentially recognized by regulatory (helper or suppressor) 
T  cells, whereas the unique tumor-specific UV antigens may be analogous to class I 
antigens, recognized by effector lymphocytes mediating cytolytic responses and per- 
haps delayed-type hypersensitivity responses. 
The regularity by which we isolated antigenic variants from UV-treated mice after 
transplantation with the 1591-RE tumor suggests that nonheritable changes in antigen 
expression  might  account  for  our  findings.  It  has  been  shown,  for  example,  that 
murine leukemia virus-induced thymoma cells can rapidly lose viral surface antigens 
to  escape destruction  by the  host's  immune system;  interestingly,  such  escape was 
reportedly  (21)  rare in fully immunocompetent normal mice but  rather frequent  in 
partially immunosuppressed  animals.  So far, however, we have failed to detect  any 
spontaneous  phenotypic reversion  to  the  parental  (i.e.,  the  1591-RE)  phenotype in 
the  1591-UVS  tumor lines isolated  from UV-treated recipients or in the  1591-PRO 
tumor cell  lines  isolated  from normal  recipients  (12),  despite  prolonged  passage of 
several of both types of these tumor cell lines in vitro or repeated passage in vivo in 
nude mice. Thus, it appears that the phenotypically different  1591-UVS sublines we 
have  isolated  are  heritable  variants.  In  addition  to  the  loss  of a  1591-RE-specific 
antigen, we found  that  most of the variant  1591-UVS  tumors showed a  progressive 
growth behavior in normal mice. However, 3 of the  11  1591-UVS tumors remained 
regressor tumors after passage through UV-treated mice, and three other  1591-UVS 
tumors were still  rejected  by >50%  of the  normal  recipients.  In contrast,  all of the 
1591-PRO tumors progressed in more than >80% of the normal recipients (12).  We 
are presently exploring the reasons for the differences in progressive growth behavior 
between some 1591-UVS tumors and the  1591-PRO tumors. 
Considering the very effective variant selection by the UV-treated mice, one has to 
ask how  these  antigenic  tumors,  such  as  1591-RE,  could  ever have arisen  in  UV- URBAN,  HOLLAND,  KRIPKE, AND SCHREIBER  1039 
treated mice. The answer may lie in our previous observation that beginning at 8 mo 
of age  normal  mice  increasingly  fail  to  mount  a  primary  tumor-specific immune 
response to the 1591-RE tumor in vivo and in vitro (11). (These old mice do not select 
for antigenic variants LI. Urban, unpubished results].) Thus, in agreement with earlier 
suggestions of others (25, 26) it is not unlikely that at least in some of the older mice 
developing tumors, both UV-treatment and advanced age jointly contribute to the 
development of many highly antigenic tumors after UV-treatment; especially as UV- 
induced tumors  tend to have a  long latency period  (such as  >6  mo  in  C3H  mice 
[2]).  Whereas  other  and  especially  younger  UV-treated  mice  may  have  retained 
partial immunocompetence at the time of tumorigenesis, the escape of UV-induced 
tumors from the immune response in these mice might have involved not only the loss 
of existing  antigenic  determinants,  but  also  the  acquisition  of new  determinants. 
These antigenic changes may be analogous to the so-called "antigenic variation" of 
slow  viruses  during  persistent  infection,  in  which  the  host  fails  to  adjust  quickly 
enough to the constantly arising antigenic variants (27). 
In conclusion, we find that UV-treated mice select for antigenically altered tumor 
variants, many of which exhibit an increased progressive growth potential in normal 
mice. This immunoselection appears to be related to the residual potential of UV- 
treated mice to activate tumor-specific lymphocyte clones despite the reduced tumor 
resistance  (3,  4)  and  the  partial  immunosuppression  (22,  23)  in  these  mice.  Such 
partial  immune  suppression  may allow  more  time  for the  tumor  to  generate and 
expand antigenic variants that constantly arise because of the high genetic instability 
inherent in the malignant cell populations (24). One might expect that in humans as 
well,  the  degree of immunocompetence of an  individual  markedly  influences  the 
immunogenicity of the developing tumor. For example, it is possible the concomitant 
tumor  immunity  in  cancer-bearing  individuals  leads  to  the  selection  of antigenic 
tumor  variants.  Our  findings  also  suggest  that  incomplete  or  partially  effective 
immunotherapeutic regimens may lead to the rapid development of lowly immuno- 
genie tumor variants. 
Summary 
It has previously been shown that mice exposed to ultraviolet radiation (UV) fail 
to reject highly immunogenie UV-induced tumors, which are regularly rejected by 
normal  mice.  The  present  study  shows,  however,  that  this  immunosuppresion  is 
incomplete,  as  UV-treated  mice  can  still  mount  certain  tumor-specific  immune 
responses and reject smaller inocula of tumor cells that regularly grow progressively 
in athymic nude mice. Furthermore, all tumor cell lines that were reisolated from the 
tumor mass resulting from one tumor passage through UV-treated recipients heritably 
lost  a  tumor-specific  determinant  present  on  the  parental  tumor  cells  used  for 
transplantation, and a large percentage of these reisolated variant tumors had changed 
to progressively growing tumors, in that they were no longer rejected by normal mice. 
In contrast, none of the tumors reisolated from passage through athymic nude mice 
or anti-idiotypieally suppressed mice showed this change in antigenicity and progres- 
sive growth behavior. Thus, it appears that the phenotypic change in tumors reisolated 
from UV-treated mice was caused by immunoselection, and that the tumor-specific 
immunity in these mice apparently restrained the outgrowth of the parental tumor 
cells despite the partial immunosuppression. Because of the regularity at which tumor 1040  TUMOR  VARIANT SELECTION  BY  IMMUNOSUPPRESSED  HOSTS 
variants arose in the UV-treated mice after tumor transplantation, it appears that the 
partial irnmunosuppression caused by UV-treatment may have favored the outgrowth 
of antigenic variants from  the parental tumor cell population, possibly by allowing 
more time  for the generation of tumor variants.  A  similar immunoselection process 
might  be  part  of tumor  progression  during  tumor  development  and  preferentially 
occur in cancer-bearing individuals showing concomitant tumor immunity. 
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